The FDA has received reports of people hospitalized after measuring compounded semaglutide in the wrong units. How a multi-dose vial creates that risk, and the overdose symptoms that need urgent care.
Retatrutide is still in clinical trials and is not approved anywhere, yet vials are sold as research chemicals. Why trial results do not transfer to an unregulated product of unknown content.
Compounders could copy semaglutide while it was on the FDA shortage list. The FDA declared the shortage over on February 21, 2025, and the grace periods ended that spring. What is still allowed, and what that means for anyone still buying a compounded version.
Both are sold to raise growth hormone, and neither is an approved medicine. What raising growth hormone is known to do to blood sugar and fluid balance, and what is simply unstudied.
TB-500 is sold as a synthetic fragment of thymosin beta-4, a protein that has been studied in humans in a few narrow settings. Why those trials do not cover what is in a gray-market vial.
Almost all of the BPC-157 research is in rats and cell cultures. What those studies found, how little has been tested in people, and what the FDA said about its safety when it reviewed it for compounding.